We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.15%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$27.8M
Cap. Flow
-$11.1M
Cap. Flow %
-4.59%
Top 10 Hldgs %
37.51%
Holding
109
New
14
Increased
27
Reduced
32
Closed
36

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$7.67M
2
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$5.23M
3
PFE icon
Pfizer
PFE
+$4.48M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$3.65M
5
GSK icon
GSK
GSK
+$3.41M

Top Sells

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$9.89M
2
AET
Aetna Inc
AET
+$5.01M
3
AGN
Allergan plc
AGN
+$4.99M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.37M
5
VWR
VWR Corporation
VWR
+$3.05M

Sector Composition

Rank Sector Weight
1 Healthcare 87.52%
2 Financials 2.14%
3 Energy 0%
4 Industrials 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
51
DELISTED
Medicines Co
MDCO
$927K 0.38%
27,300
+6,700
+33% +$238K
EXEL icon
52
Exelixis
EXEL
$13.3B
$908K 0.38%
60,870
+10,570
+21% +$152K
TEVA icon
53
Teva Pharmaceuticals
TEVA
$40.8B
$868K 0.36%
23,933
-109,500
-82% -$4.37M
PPH icon
54
VanEck Pharmaceutical ETF
PPH
$959M
$819K 0.34%
+15,600
New +$834K
CLVS
55
DELISTED
Clovis Oncology, Inc.
CLVS
$817K 0.34%
18,400
+10,100
+122% +$355K
REGN icon
56
Regeneron Pharmaceuticals
REGN
$78.5B
$808K 0.33%
+2,200
New +$837K
DERM
57
DELISTED
Dermira, Inc.
DERM
$761K 0.31%
25,088
-1,100
-4% -$35.5K
ONCE
58
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$739K 0.31%
14,800
+9,000
+155% +$482K
ENDP
59
DELISTED
Endo International plc
ENDP
$728K 0.3%
44,196
-64,500
-59% -$1.14M
NVRO
60
DELISTED
NEVRO CORP.
NVRO
$684K 0.28%
9,420
-3,164
-25% -$271K
AMGN icon
61
Amgen
AMGN
$208B
$637K 0.26%
4,358
-3,500
-45% -$527K
OCRX
62
DELISTED
Ocera Therapeutics, Inc.
OCRX
$476K 0.2%
226,442
+123,300
+120% +$288K
NBIX icon
63
Neurocrine Biosciences
NBIX
$16.8B
$445K 0.18%
11,500
-700
-6% -$31.7K
ARRY
64
DELISTED
Array Biopharma Inc
ARRY
$247K 0.1%
28,100
+18,100
+181% +$133K
OXFD
65
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$240K 0.1%
16,056
-95,599
-86% -$1.34M
SPNC
66
DELISTED
Spectranetics Corp
SPNC
$236K 0.1%
9,626
-42,400
-81% -$997K
SRPT icon
67
Sarepta Therapeutics
SRPT
$1.57B
$230K 0.1%
+8,400
New +$337K
PARN
68
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$227K 0.09%
328,781
-120,021
-27% -$143K
DVAX
69
DELISTED
Dynavax Technologies
DVAX
$224K 0.09%
+56,800
New +$416K
BAX icon
70
Baxter International
BAX
$13.5B
$208K 0.09%
4,700
-3,609
-43% -$167K
RXDX
71
DELISTED
Ignyta, Inc.
RXDX
$138K 0.06%
26,012
-26,188
-50% -$153K
CBIO
72
Crescent Biopharma
CBIO
$537M
$88K 0.04%
+145
New +$90.5K
A icon
73
Agilent Technologies
A
$39.1B
– –
-30,585
Closed -$1.44M
ANIP icon
74
ANI Pharmaceuticals
ANIP
$1.8B
– –
-4,600
Closed -$305K
BHC icon
75
Bausch Health
BHC
$2.58B
– –
-22,400
Closed -$550K
1 2
3
4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Endurant Capital Management held 109 positions worth $242M, down 10% from $270M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Endurant Capital Management withdrew a net $11.1M in Q4 2016, closing 36 positions and reducing 32 holdings. Its most notable exit was Amsurg Corp, an estimated $9.89M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Financials and Energy.

Against the trend, Endurant Capital Management opened a new position in Pfizer worth $4.52M.

  • Endurant Capital Management's largest Q4 2016 buy was Pfizer: 146,611 shares worth $4.52M.
  • Endurant Capital Management added most to Becton Dickinson in Q4 2016, an estimated $7.67M increase.
  • Endurant Capital Management's biggest Q4 2016 reduction was Aetna Inc, cutting an estimated $5.01M.
  • Endurant Capital Management fully exited Amsurg Corp in Q4 2016, selling an estimated $9.89M.
  • Endurant Capital Management's ten largest holdings make up 38% of its $242M portfolio in Q4 2016.
  • Endurant Capital Management opened 14 new positions and closed 36 in Q4 2016.
  • Endurant Capital Management's portfolio value fell 10% quarter-over-quarter to $242M.

Based on Endurant Capital Management's 13F filing for Q4 2016, filed 15 Feb 2017.